Cystic fibrosis and the innate immune system: Therapeutic implications

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 1, 2011, Pages 8-22

  Conese, Massimo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Airway epithelial cells; CF transmembrane conductance regulator (CFTR); Cystic fibrosis (CF); Lymphocytes; Macrophages; Neutrophils

Indexed keywords

ACETYLCYSTEINE; AMELUBANT; AMITRIPTYLINE; CERAMIDE; CORTICOSTEROID; DOCOSAHEXAENOIC ACID; GLUTATHIONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; STAT1 PROTEIN; TOLL LIKE RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL FUNCTION; CLINICAL TRIAL; CYSTIC FIBROSIS; GENE MUTATION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LOSS OF FUNCTION MUTATION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PHAGOSOME; PNEUMONIA; RESPIRATORY EPITHELIUM; RHEUMATOID ARTHRITIS; RNA STABILITY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 79953006218     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153011794982022     Document Type: Article

References (184)

1. Rommens, J.M.; Iannuzzi, M.C.; Kerem, B.; Drumm, M.L. and Melmer, G. (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science, 245, 1059-1065.
2. Riordan, J.R.; Rommens, J.M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.L.; Drumm, M.L.; Iannuzzi, M.C.; Collins, F.S. and Tsui, L.-C. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245, 1066-1073 [Erratum, Science, 1989, 245, 1437].
3. Kerem, B.; Rommens, J.M.; Buchanan, J.A.; Markiewicz, D.; Cox, T.K.; Chakravarti, A.; Buchwald, M. and Tsui, L.C. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science, 245, 1073-1080.
4. Quinton, P.M. (1986) Missing Cl conductance in cystic fibrosis. Am. J. Physiol., 251, C649-C652.
5. Quinton, P.M. (1999) Physiological basis of cystic fibrosis: a historical perspective. Physiol. Rev., 79, S3-S22.
6. Boucher, R.C. (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J., 23, 146-158.
7. Rowe, S.M.; Miller, S. and Sorscher, E.J. (2005) Cystic fibrosis. N. Engl. J. Med., 352, 1992-2001.
8. Armstrong, D.; Grimwood, K.; Carlin, J.B.; Carzino, R.; Hull, J.; Olinsky, A. and Phelan, P.D. (1998) Severe viral respiratory infections in infants with cystic fibrosis. Pediatr. Pulmonol., 26, 371-379.
9. Bence, N.F.; Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-1555.
10. Rottner, M.; Freyssinet, J.M. and Martinez, M.C. (2009) Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir. Res., 10, 23.
11. + permeability in cystic fibrosis human primary cell cultures. J. Physiol., 405, 77-103.
12. Matsui, H.; Grubb, B.R.; Tarran, R.; Randell, S.H.; Gatzy, J.T.; Davis, C.W. and Boucher, R.C. (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell, 95, 1005-1015.
13. Worlitzsch, D.; Tarran, R.; Ulrich, M.; Schwab, U.; Cekici, A.; Meyer, K.C.; Birrer, P.; Bellon, G.; Berger, J.; Weiss, A.; Botzenhart, K.; Yankaskas, J.R.; Randell, S.; Boucher, R.C. and Doring, G. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest., 109, 317-325.
14. Hoiby, N. Microbiology of cystic fibrosis. In Cystic fibrosis, Hodson, M. E.; Geddes, D. M., Eds. Chapman & Hall: London, 1995, pp. 75-98.
15. Matsui, H.; Wagner, V.E.; Hill, D.B.; Schwab, U.E.; Rogers, T.D.; Button, B.; Taylor, R.M.N.; Superfine, R.; Rubinstein, M.; Iglewski, B.H. and Boucher, R.C. (2006) A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc. Natl. Acad. Sci. USA, 103, 18131-18136.
16. Matsui, H.; Verghese, M.W.; Kesimer, M.; Schwab, U.E.; Randell, S.H.; Sheehan, J.K.; Grubb, B.R. and Boucher, R.C. (2005) Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J. Immunol., 175, 1090-1099.
17. Wine, J.J. and Joo, N.S. (2004) Submucosal glands and airway defense. Proc. Am. Thorac. Soc., 1, 47-53.
18. Davis, P.B.; Drumm, M. and Konstan, M.W. (1996) Cystic Fibrosis. Am. J. Respir. Crit. Care Med., 154, 1229-1256.
19. Khan, T.Z.; Wagener, J.S.; Bost, T.; Martinez, J.; Accurso, F.J. and Riches, D.W.H. (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med., 151, 1075-1082.
20. Saadane, A.; Soltys, J. and Berger, M. (2005) Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J. Allergy Clin. Immunol., 115, 405-411.
21. Tirouvanziam, R.; de Bentzmann, S.; Hubeau, C.; Hinnrasky, J.; Jacquot, J.; Péault, B. and Puchelle, E. (2000) Inflammation and infection in naive human cystic fibrosis airway xenografts. Am. J. Respir. Cell Mol. Biol., 23, 121-127.
22. Weber, A.J.; Soong, G.; Bryan, R.; Saba, S. and Prince, A. (2001) Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am. J. Physiol. Lung Cell. Mol. Physiol., 281, L71-L78.
23. Kube, D.; Sontich, U.; Fletcher, D. and Davis, P.B. (2001) Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am. J. Physiol. Lung Cell. Mol. Physiol., 280, L493-L502.
24. Aldallal, N.; McNaughton, E.E.; Manzel, L.J.; Richards, A.M.; Zabner, J.; Ferkol, T.W. and Look, D.C. (2002) Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am. J. Respir. Crit Care Med., 166, 1248-1256.
25. Becker, M.N.; Sauer, M.S.; Muhlebach, M.S.; Hirsh, A.J.; Wu, Q.; Verghese, M.W. and Randell, S.H. (2004) Cytokine secretion by cystic fibrosis airway epithelial cells. Am. J. Respir. Crit. Care Med., 169, 645-653.
26. Carrabino, S.; Carpani, D.; Livraghi, A.; Di Cicco, M.; Costantini, D.; Copreni, E.; Colombo, C. and Conese, M. (2006) Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J. Cyst. Fibros., 5, 113-119.
27. Stecenko, A.A.; King, G.; Torii, K.; Breyer, R.M.; Dworski, R.; Blackwell, T.S.; Christman, J.W. and Brigham, K.L. (2001) Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation, 25, 145-155.
28. Perez, A.; Issler, A.C.; Cotton, C.U.; Kelley, T.J.; Verkman, A.S. and Davis, P.B. (2007) CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am. J. Physiol. Lung Cell Mol. Physiol., 292, L383-L395.
29. Hunter, M.J.; Treharne, K.J.; Winter, A.K.; Cassidy, D.M.; Land, S. and Mehta, A. (2010) Expression of wild-type CFTR suppresses NF-kappaB-driven inflammatory signalling. PLoS One, 5, e11598.
30. Vij, N.; Mazur, S. and Zeitlin, P.L. (2009) CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One, 4, e4664.
31. Kowalski, M.P. and Pier, G.B. (2004) Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J. Immunol., 172, 418-425.
32. Diamond, G.; Legarda, D.; Ryan, L.K. (2000) The innate immune response of the respiratory epithelium. Immunol. Rev., 173, 27-38.
33. Bals, R. and Hiemstra, P.S. (2004) Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur. Respir. J., 23, 327-333.
34. Muir, A.; Soong, G.; Sokol, S.; Reddy, B.; Gomez, M.I.; Van Heeckeren, A. and Prince, A. (2004) Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am. J. Respir. Cell. Mol. Biol., 30, 777-783.
35. Takeda, K.; Kaisho, T. and Akira, S. (2003) Toll-like receptors. Annu. Rev. Immunol., 21, 335-376.
36. Devaney, J.M.; Greene, C.M.; Taggart, C.C.; Carroll, T.P.; O'Neill, S.J. and McElvaney, N.G. (2003) Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett., 544, 129-132.
37. Takeda, K. and Akira, S. (2005) Toll-like receptors in innate immunity. Int. Immunol., 17, 1-14.
38. Lee, F.S.; Peters, R.T.; Dang, L.C. and Maniatis, T. (1998) MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc. Natl. Acad. Sci. USA, 95, 9319-9324.
39. Zhao, Q. and Lee, F.S. (1999) Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta. J. Biol. Chem., 274, 8355-8358.
40. Greene, C.M.; Carroll, T.P.; Smith, S.G.; Taggart, C.C.; Devaney, J.; Griffin, S.; O'Neill, S.J. and McElvaney, N.G. (2005) TLRinduced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J. Immunol., 174, 1638-1646.
41. Li, J.; Johnson, X.D.; Iazvovskaia, S.; Tan, A.; Lin, A. and Hershenson, M.B. (2003) Signaling intermediates required for NFkappa B activation and IL-8 expression in CF bronchial epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol., 284, L307-L315.
42. Li, J.D.; Feng, W.; Gallup, M.; Kim, J.H.; Gum, J.; Kim, Y. and Basbaum, C. (1998) Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc. Natl. Acad. Sci. USA, 95, 5718-5723.
43. Knorre, A.; Wagner, M.; Schaefer, H.E.; Colledge, W.H. and Pahl, H.L. (2002) DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs. Biol. Chem., 383, 271-282.
44. Verhaeghe, C.; Remouchamps, C.; Hennuy, B.; Vanderplasschen, A.; Chariot, A.; Tabruyn, S.P.; Oury, C. and Bours, V. (2007) Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem. Pharmacol., 73, 1982-1994.
45. Muselet-Charlier, C.; Roque, T.; Boncoeur, E.; Chadelat, K.; Clement, A.; Jacquot, J. and Tabary, O. (2007) Enhanced IL-1betainduced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NFkappaB signaling. Biochem. Biophys. Res. Commun., 357, 402-407.
46. Berube, J.; Roussel, L.; Nattagh, L. and Rousseau, S. (2010) Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and ERK MAPKs, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa. J. Biol. Chem., 285, 22299-22307.
47. Ribeiro, C.M. (2006) The role of intracellular calcium signals in inflammatory responses of polarised cystic fibrosis human airway epithelia. Drugs R. D., 7, 17-31.
48. Tabary, O.; Boncoeur, E.; de Martin, R.; Pepperkok, R.; Clement, A.; Schultz, C. and Jacquot, J. (2006) Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells. Cell Signal, 18, 652-660.
49. de Winter-de Groot, K.M. and van der Ent, C.K. (2005) Nitric oxide in cystic fibrosis. J. Cyst. Fibros., 4 (Suppl 2), 25-29.
50. Kelley, T.J. and Elmer, H.L. (2000) In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J. Clin. Invest., 106, 403-410.
51. Zheng, S.; Xu, W.; Bose, S.; Banerjee, A.K.; Haque, S.J. and Erzurum, S.C. (2004) Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol., 287, L374-L381.
52. Darling, K.E. and Evans, T.J. (2003) Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect. Immun., 71, 2341-2349.
53. Zheng, S.; De Bishnu, P.; Choudhary, S.; Comhair, S.A.; Goggans, T.; Slee, R.; Williams, B.R.; Pilewski, J.; Haque, S.J. and Erzurum, S.C. (2003) Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity, 18, 619-630.
54. Sato, Y.; Walley, K.R.; Klut, M.E.; English, D.; D'Yachkova, Y.; Hogg, J.C. and van Eeden, S.F. (1999) Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression. Am. J. Respir. Crit. Care Med., 159, 1469-1476.
55. O'Malley, Y.Q.; Reszka, K.J. and Britigan, B.E. (2004) Direct oxidation of 2', 7'-dichlorodihydrofluorescein by pyocyanin and other redox-active compounds independent of reactive oxygen species production. Free Radic. Biol. Med., 36, 90-100.
56. Lucidi, V.; Ciabattoni, G.; Bella, S.; Barnes, P.J. and Montuschi, P. (2008) Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. Free Radic. Biol. Med., 45, 913-919.
57. Robroeks, C.M.; Rosias, P.P.; van Vliet, D.; Jobsis, Q.; Yntema, J.B.; Brackel, H.J.; Damoiseaux, J.G.; den Hartog, G.M.; Wodzig, W.K. and Dompeling, E. (2008) Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr. Allergy Immunol., 19, 652-659.
58. Starosta, V.; Rietschel, E.; Paul, K.; Baumann, U. and Griese, M. (2006) Oxidative changes of bronchoalveolar proteins in cystic fibrosis. Chest, 129, 431-437.
59. Kettle, A.J.; Chan, T.; Osberg, I.; Senthilmohan, R.; Chapman, A.L.; Mocatta, T.J. and Wagener, J.S. (2004) Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am. J. Respir. Crit. Care Med., 170, 1317-1323.
60. Velsor, L.W.; Kariya, C.; Kachadourian, R. and Day, B.J. (2006) Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell. Mol. Biol., 35, 579-586.
61. Velsor, L.W.; van Heeckeren, A. and Day, B.J. (2001) Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Physiol. Lung Cell. Mol. Physiol., 281, L31-L38.
62. Cantin, A.M.; Bilodeau, G.; Ouellet, C.; Liao, J. and Hanrahan, J.W. (2006) Oxidant stress suppresses CFTR expression. Am. J. Physiol. Cell Physiol., 290, C262-C270.
63. Jacquot, J.; Tabary, O.; Le Rouzic, P. and Clement, A. (2008) Airway epithelial cell inflammatory signalling in cystic fibrosis. Int. J. Biochem. Cell Biol., 40, 1703-1715.
64. Trudel, S.; Kelly, M.; Fritsch, J.; Nguyen-Khoa, T.; Therond, P.; Couturier, M.; Dadlez, M.; Debski, J.; Touqui, L.; Vallee, B.; Ollero, M.; Edelman, A. and Brouillard, F. (2009) Peroxiredoxin 6 fails to limit phospholipid peroxidation in lung from Cftr-knockout mice subjected to oxidative challenge. PLoS One, 4, e6075.
65. Roum, J.H.; Buhl, R.; McElvaney, N.G.; Borok, Z. and Crystal, R.G. (1993) Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol., 75, 2419-2424.
66. Gao, L.; Kim, K.J.; Yankaskas, J.R. and Forman, H.J. (1999) Abnormal glutathione transport in cystic fibrosis airway epithelia. Am. J. Physiol., 277, L113-L118.
67. Hudson, V.M. (2001) Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med., 30, 1440-1461.
68. Teichgraber, V.; Ulrich, M.; Endlich, N.; Riethmuller, J.; Wilker, B.; De Oliveira-Munding, C.C.; van Heeckeren, A.M.; Barr, M.L.; von Kurthy, G.; Schmid, K.W.; Weller, M.; Tummler, B.; Lang, F.; Grassme, H.; Doring, G. and Gulbins, E. (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med., 14, 382-391.
69. Kolesnick, R.N.; Goni, F.M. and Alonso, A. (2000) Compartmentalization of ceramide signaling: physical foundations and biological effects. J. Cell Physiol., 184, 285-300.
70. Doring, G. and Gulbins, E. (2009) Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol., 11, 208-216.
71. Guilbault, C.; De Sanctis, J.B.; Wojewodka, G.; Saeed, Z.; Lachance, C.; Skinner, T.A.; Vilela, R.M.; Kubow, S.; Lands, L.C.; Hajduch, M.; Matouk, E. and Radzioch, D. (2008) Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am. J. Respir. Cell Mol. Biol., 38, 47-56.
72. Becker, K.A.; Riethmuller, J.; Luth, A.; Doring, G.; Kleuser, B. and Gulbins, E. (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am. J. Respir. Cell Mol. Biol., 42, 716-724.
73. Luciani, A.; Villella, V.R.; Vasaturo, A.; Giardino, I.; Raia, V.; Pettoello-Mantovani, M.; D'Apolito, M.; Guido, S.; Leal, T.; Quaratino, S. and Maiuri, L. (2009) SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J. Immunol., 183, 2775-2784.
74. He, C.; Levine, B. (2010) The Beclin 1 interactome. Curr. Opin. Cell Biol., 22, 140-149.
75. Ravikumar, B.; Sarkar, S.; Davies, J.E.; Futter, M.; Garcia- Arencibia, M.; Green-Thompson, Z.W.; Jimenez-Sanchez, M.; Korolchuk, V.I.; Lichtenberg, M.; Luo, S.; Massey, D.C.; Menzies, F.M.; Moreau, K.; Narayanan, U.; Renna, M.; Siddiqi, F.H.; Underwood, B.R.; Winslow, A.R. and Rubinsztein, D.C. (2010) Regulation of Mammalian autophagy in physiology and pathophysiology. Physiol. Rev., 90, 1383-1435.
76. Luciani, A.; Villella, V.R.; Esposito, S.; Brunetti-Pierri, N.; Medina, D.; Settembre, C.; Gavina, M.; Pulze, L.; Giardino, I.; Pettoello-Mantovani, M.; D'Apolito, M.; Guido, S.; Masliah, E.; Spencer, B.; Quaratino, S.; Raia, V.; Ballabio, A. and Maiuri, L. (2010) Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell Biol., 12, 863-875.
77. Skerrett, S.J.; Liggitt, H.D.; Hajjar, A.M. and Wilson, C.B. (2004) Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. J. Immunol., 172, 3377-3381.
78. Cheung, D.O.Y.; Halsey, K. and Speert, D.P. (2000) Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect. Immun., 68, 4585-4592.
79. Ojielo, C.I.; Cooke, K.; Mancuso, P.; Standiford, T.J.; Olkiewicz, K.M.; Clouthier, S.; Corrion, L.; Ballinger, M.N.; Toews, G.B.; Paine, R. 3rd. and Moore, B.B. (2003) Defective phagocytosis and clearance of Pseudomonas aeruginosa in the lung following bone marrow transplantation. J. Immunol., 171, 4416-4424.
80. Hashimoto, S.; Pittet, J.F.; Hong, K.; Folkesson, H.; Bagby, G.; Kobzik, L.; Frevert, C.; Watanabe, K.; Tsurufuji, S. and Wiener- Kronish, J. (1996) Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections. Am. J. Physiol. Lung Cell. Mol. Physiol., 270, L819-L828.
81. Kooguchi, K.; Hashimoto, S.; Kobayashi, A.; Kitamura, Y.; Kudoh, I.; Wiener-Kronish, J. and Sawa, T. (1998) Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect. Immun., 66, 3164-3169.
82. Hauschildt, S. and Kleine, B. (1995) Bacterial stimulators of macrophages. Int. Rev. Cytol., 161, 263-331.
83. Stanley, E.; Lieschke, G.J.; Grail, D.; Metcalf, D.; Hodgson, G.; Gall, J.A.; Maher, D.W.; Cebon, J.; Sinickas, V. and Dunn, A.R. (1994) Granulocyte/macrophage colony-stimulating factordeficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA, 91, 5592-5596.
84. Trapnell, B.C. and Whitsett, J.A. (2002) Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophagemediated innate host defense. Annu. Rev. Physiol., 64, 775-802.
85. Ikegami, M.; Ueda, T.; Hull, W.; Whitsett, J.A.; Mulligan, R.C.; Dranoff, G. and Jobe, A.H. (1996) Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am. J. Physiol., 270, L650-L658.
86. Dranoff, G.; Crawford, A.D.; Sadelain, M.; Ream, B.; Rashid, A.; Bronson, R.T.; Dickersin, G.R.; Bachurski, C.J.; Mark, E.L.; Whitsett, J.A. and Mulligan, R.C. (1994) Involvement of granulocytemacrophage colony-stimulating factor in pulmonary homeostasis. Science, 264, 713-716.
87. LeVine, A.M.; Reed, J.A.; Kurak, K.E.; Cianciolo, E. and Whitsett, J.A. (1999) GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J. Clin. Invest., 103, 563-569.
88. Paine, R. 3rd; Preston, A.M.; Wilcoxen, S.; Jin, H.; Siu, B.B.; Morris, S.B.; Reed, J.A.; Ross, G.; Whitsett, J.A. and Beck, J.M. (2000) Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J. Immunol., 164, 2602-2609.
89. Gonzalez-Juarrero, M.; Hattle, J.M.; Izzo, A.; Junqueira-Kipnis, A.P.; Shim, T.S.; Trapnell, B.C.; Cooper, A.M. and Orme, I.M. (2005) Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J. Leukoc. Biol., 77, 914-922.
90. Ballinger, M.N.; Paine, R. 3rd; Serezani, C.H.; Aronoff, D.M.; Choi, E.S.; Standiford, T.J.; Toews, G.B. and Moore, B.B. (2006) Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa. Am. J. Respir. Cell. Mol. Biol., 34, 766-774.
91. Shibata, Y.; Berclaz, P.Y.; Chroneos, Z.C.; Yoshida, M.; Whitsett, J.A. and Trapnell, B.C. (2001) GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity, 15, 557-567.
92. Berclaz, P.Y.; Carey, B.; Fillipi, M.D.; Wernke-Dollries, K.; Geraci, N.; Cush, S.; Richardson, T.; Kitzmiller, J.; O'Connor, M.; Hermoyian, C.; Korfhagen, T.; Whitsett, J.A. and Trapnell, B.C. (2007) GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS. Am. J. Respir. Cell Mol. Biol., 36, 114-121.
93. Koller, D.Y.; Nething, I.; Otto, J.; Urbanek, R. and Eichler, I. (1997) Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity. Am. J. Respir. Crit. Care Med., 155, 1050-1054.
94. Moser, C.; Jensen, P.O.; Pressler, T.; Frederiksen, B.; Lanng, S.; Kharazmi, A.; Koch, C. and Hoiby, N. (2005) Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Apmis, 113, 400-409.
95. Jensen, P.O.; Moser, C.; Kharazmi, A.; Presler, T.; Koch, C. and Hoiby, N. (2006) Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. J. Cyst. Fibros., 5, 145-151.
96. Adib-Conquy, M.; Pedron, T.; Petit-Bertron, A.F.; Tabary, O.; Corvol, H.; Jacquot, J.; Clement, A. and Cavaillon, J.M. (2008) Neutrophils in cystic fibrosis display a distinct gene expression pattern. Mol. Med., 14, 36-44.
97. Di, A.; Brown, M.E.; Deriy, L.V.; Li, C.; Szeto, F.L.; Chen, Y.; Huang, P.; Tong, J.; Naren, A.P.; Bindokas, V.; Palfrey, H.C. and Nelson, D.J. (2006) CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol., 8, 933-944.
98. Haggie, P.M. and Verkman, A.S. (2007) Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J. Biol. Chem., 282, 31422-31428.
99. Zhang, Y.; Li, X.; Grassme, H.; Doring, G. and Gulbins, E. (2010) Alterations in ceramide concentration and pH determine the release of reactive oxygen species by Cftr-deficient macrophages on infection. J. Immunol., 184, 5104-5111.
100. Moser, C.; Kjaergaard, S.; Pressler, T.; Kharazmi, A.; Koch, C. and Hoiby, N. (2000) The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Apmis, 108, 329-335.
101. Hartl, D.; Griese, M.; Kappler, M.; Zissel, G.; Reinhardt, D.; Rebhan, C.; Schendel, D.J. and Krauss-Etschmann, S. (2006) Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J. Allergy Clin. Immunol., 117, 204-211.
102. Murphy, B.S.; Bush, H.M.; Sundareshan, V.; Davis, C.; Hagadone, J.; Cory, T.J.; Hoy, H.; Hayes, D.Jr.; Anstead, M.I. and Feola, D.J. (2010) Characterization of macrophage activation states in patients with cystic fibrosis. J. Cyst. Fibros., 9, 314-322.
103. Dubin, P.J.; McAllister, F. and Kolls, J.K. (2007) Is cystic fibrosis a TH17 disease? Inflamm. Res., 56, 221-227.
104. McAllister, F.; Henry, A.; Kreindler, J.L.; Dubin, P.J.; Ulrich, L.; Steele, C.; Finder, J.D.; Pilewski, J.M.; Carreno, B.M.; Goldman, S.J.; Pirhonen, J. and Kolls, J.K. (2005) Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immunol., 175, 404-412.
105. Corvol, H.; Fitting, C.; Chadelat, K.; Jacquot, J.; Tabary, O.; Boule, M.; Cavaillon, J.M. and Clement, A. (2003) Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol., 284, L997-L1003.
106. Makam, M.; Diaz, D.; Laval, J.; Gernez, Y.; Conrad, C.K.; Dunn, C.E.; Davies, Z.A.; Moss, R. B.; Herzenberg, L.A.; Herzenberg, L.A. and Tirouvanziam, R. (2009) Activation of critical, hostinduced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc. Natl. Acad. Sci. USA, 106, 5779-5783.
107. Tirouvanziam, R.; Gernez, Y.; Conrad, C.K.; Moss, R.B.; Schrijver, I.; Dunn, C.E.; Davies, Z.A.; Herzenberg, L.A. and Herzenberg, L.A. (2008) Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc. Natl. Acad. Sci. USA, 105, 4335-4339.
108. Petit-Bertron, A.F.; Tabary, O.; Corvol, H.; Jacquot, J.; Clement, A.; Cavaillon, J.M. and Adib-Conquy, M. (2008) Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine, 41, 54-60.
109. Conese, M.; Copreni, E.; Di Gioia, S.; De Rinaldis, P. and Fumarulo, R. (2003) Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease. J. Cyst. Fibros., 2, 129-135.
110. Downey, D.G.; Bell, S.C. and Elborn, J.S. (2009) Neutrophils in cystic fibrosis. Thorax, 64, 81-88.
111. Watt, A.P.; Courtney, J.; Moore, J.; Ennis, M. and Elborn, J.S. (2005) Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax, 60, 659-664.
112. Vandivier, R.W.; Fadok, V.A.; Hoffmann, P.R.; Bratton, D.L.; Penvari, C.; Brown, K.K.; Brain, J.D.; Accurso, F.J. and Henson, P.M. (2002) Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J. Clin. Invest., 109, 661-670.
113. Vandivier, R.W.; Richens, T.R.; Horstmann, S.A.; deCathelineau, A.M.; Ghosh, M.; Reynolds, S.D.; Xiao, Y.Q.; Riches, D.W.; Plumb, J.; Vachon, E.; Downey, G.P. and Henson, P.M. (2009) Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. Am. J. Physiol. Lung Cell. Mol. Physiol., 297, L677- L686.
114. Tabary, O.; Corvol, H.; Boncoeur, E.; Chadelat, K.; Fitting, C.; Cavaillon, J.M.; Clement, A. and Jacquot, J. (2006) Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. Am. J. Physiol. Lung Cell. Mol. Physiol., 290, L588-L596.
115. Hartl, D.; Latzin, P.; Hordijk, P.; Marcos, V.; Rudolph, C.; Woischnik, M.; Krauss-Etschmann, S.; Koller, B.; Reinhardt, D.; Roscher, A.A.; Roos, D. and Griese, M. (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat. Med., 13, 1423-1430.
116. Walker, T.S.; Tomlin, K.L.; Worthen, G.S.; Poch, K.R.; Lieber, J.G.; Saavedra, M.T.; Fessler, M.B.; Malcolm, K.C.; Vasil, M.L. and Nick, J.A. (2005) Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun., 73, 3693-3701.
117. Hubeau, C.; Lorenzato, M.; Couetil, J.P.; Hubert, D.; Dusser, D.; Puchelle, E. and Gaillard, D. (2001) Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa. Clin. Exp. Immunol., 124, 69-76.
118. Brinkmann, V. and Zychlinsky, A. (2007) Beneficial suicide: why neutrophils die to make NETs. Nat. Rev. Microbiol., 5, 577-582.
119. Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.S.; Weinrauch, Y. and Zychlinsky, A. (2004) Neutrophil extracellular traps kill bacteria. Science, 303, 1532-1535.
120. Buchanan, J.T.; Simpson, A.J.; Aziz, R.K.; Liu, G.Y.; Kristian, S.A.; Kotb, M.; Feramisco, J. and Nizet, V. (2006) DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol., 16, 396-400.
121. Clark, S.R.; Ma, A.C.; Tavener, S.A.; McDonald, B.; Goodarzi, Z.; Kelly, M.M.; Patel, K.D.; Chakrabarti, S.; McAvoy, E.; Sinclair, G.D.; Keys, E.M.; Allen-Vercoe, E.; Devinney, R.; Doig, C.J.; Green, F.H. and Kubes, P. (2007) Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med., 13, 463-469.
122. Urban, C.F.; Reichard, U.; Brinkmann, V. and Zychlinsky, A. (2006) Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell. Microbiol., 8, 668-676.
123. Urban, C.F.; Ermert, D.; Schmid, M.; Abu-Abed, U.; Goosmann, C.; Nacken, W.; Brinkmann, V.; Jungblut, P.R. and Zychlinsky, A. (2009) Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog., 5, e1000639.
124. Kessenbrock, K.; Krumbholz, M.; Schonermarck, U.; Back, W.; Gross, W.L.; Werb, Z.; Grone, H.J.; Brinkmann, V. and Jenne, D.E. (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med., 15, 623-625.
125. Hakkim, A.; Furnrohr, B.G.; Amann, K.; Laube, B.; Abed, U.A.; Brinkmann, V.; Herrmann, M.; Voll, R.E. and Zychlinsky, A. (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA, 107, 9813-9318.
126. Marcos, V.; Zhou, Z.; Yildirim, A.O.; Bohla, A.; Hector, A.; Vitkov, L.; Wiedenbauer, E. M.; Krautgartner, W.D.; Stoiber, W.; Belohradsky, B.H.; Rieber, N.; Kormann, M.; Koller, B.; Roscher, A.; Roos, D.; Griese, M.; Eickelberg, O.; Doring, G.; Mall, M.A. and Hartl, D. (2010) CXCR2 mediates NADPH oxidaseindependent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat. Med., 16, 1018-1023.
127. Porro, C.; Lepore, S.; Trotta, T.; Castellani, S.; Ratclif, L.; Battaglino, A.; Di Gioia, S.; Martinez, M.C.; Conese, M. and Maffione, A.B. (2010) Isolation and characterization of microparticles in sputum of cystic fibrosis patients. Respir. Res., 11, 94.
128. Gupta, A.K.; Hasler, P.; Holzgreve, W.; Gebhardt, S. and Hahn, S. (2005) Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum. Immunol., 66, 1146-1154.
129. Conese, M.; Romano, M.; Furnari, M.L.; Copreni, E.; de Fino, I.; Pardo, F.; Galietta, L.V.J. (2009) New genetic and pharmacological treatments for cystic fibrosis. Curr. Ped. Rev., 5, 8-27.
130. Ashlock, M.A.; Beall, R.J.; Hamblett, N.M.; Konstan, M.W.; Penland, C.M.; Ramsey, B.W.; Van Dalfsen, J.M.; Wetmore, D.R. and Campbell, P.W. 3rd. (2009) A pipeline of therapies for cystic fibrosis. Semin. Respir. Crit. Care Med., 30, 611-626.
131. Koehler, D.R.; Downey, G.P.; Sweezey, N.B.; Tanswell, A.K. and Hu, J. (2004) Lung inflammation as a therapeutic target in cystic fibrosis. Am. J. Respir. Cell Mol. Biol., 31, 377-381.
132. Nichols, D.P.; Konstan, M.W. and Chmiel, J.F. (2008) Antiinflammatory therapies for cystic fibrosis-related lung disease. Clin. Rev. Allergy Immunol., 35, 135-153.
133. Bodas, M. and Vij, N. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov. Med., 9, 346-356.
134. Funk, C.D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 294, 1871-1875.
135. Okuno, T.; Yokomizo, T.; Hori, T.; Miyano, M. and Shimizu, T. (2005) Leukotriene B4 receptor and the function of its helix 8. J. Biol. Chem., 280, 32049-32052.
136. Carpagnano, G.E.; Barnes, P.J.; Geddes, D.M.; Hodson, M.E. and Kharitonov, S.A. (2003) Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am. J. Respir. Crit. Care Med., 167, 1109-1112.
137. Konstan, M.W.; Doring, G.; Lands, L.C.; Hilliard, K.A.; Koker, P.; Bhattacharya, B.; Staab, A. and Hamilton, A.L. (2005) Results of a phase II clinical trial of BIIL 284 BS (a LTB4 receptor antagonist) for the treatment of CF lung disease. Ped. Pulmunol., 28, 125-127.
138. Moss, R.B.; Mayer-Hamblett, N.; Wagener, J.; Daines, C.; Hale, K.; Ahrens, R.; Gibson, R.L.; Anderson, P.; Retsch-Bogart, G.; Nasr, S.Z.; Noth, I.; Waltz, D.; Zeitlin, P.; Ramsey, B. and Starko, K. (2005) Randomized, double-blind, placebo-controlled, doseescalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr. Pulmonol., 39, 209-218.
139. Greene, C.M.; Branagan, P. and McElvaney, N.G. (2008) Toll-like receptors as therapeutic targets in cystic fibrosis. Expert. Opin. Ther. Targets, 12, 1481-1495.
140. Bingle, L. and Tetley, T.D. (1996) Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. Thorax, 51, 1273-1274.
141. Taggart, C.C.; Greene, C.M.; McElvaney, N.G. and O'Neill, S. (2002) Secretory leucoprotease inhibitor prevents lipopolysaccharide- induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J. Biol. Chem., 277, 33648-33653.
142. Taggart, C.C.; Cryan, S.A.; Weldon, S.; Gibbons, A.; Greene, C.M.; Kelly, E.; Low, T.B.; O'Neill, S.J. and McElvaney, N.G. (2005) Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J. Exp. Med., 202, 1659-1668.
143. Bonizzi, G. and Karin, M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol., 25, 280-288.
144. Wright, J.G. and Christman, J.W. (2003) The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am. J. Respir. Med., 2, 211-219.
145. Cabrini, G.; Bezzerri, V.; Mancini, I.; Nicolis, E.; Dechecchi, M.C.; Tamanini, A.; Lampronti, I.; Piccagli, L.; Bianchi, N.; Borgatti, M. and Gambari, R. (2010) Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds. Curr. Med. Chem., 17, 4392-4404.
146. Bezzerri, V.; Borgatti, M.; Nicolis, E.; Lampronti, I.; Dechecchi, M.C.; Mancini, I.; Rizzotti, P.; Gambari, R. and Cabrini, G. (2008) Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am. J. Respir. Cell Mol. Biol., 39, 86-96.
147. Piccagli, L.; Fabbri, E.; Borgatti, M.; Bezzerri, V.; Mancini, I.; Nicolis, E.; Dechecchi, M.C.; Lampronti, I.; Cabrini, G. and Gambari, R. (2008) Docking of molecules identified in bioactive medicinal plants extracts into the p50 NF-kappaB transcription factor: correlation with inhibition of NF-kappaB/DNA interactions and inhibitory effects on IL-8 gene expression. BMC Struct. Biol., 8, 38.
148. Piccagli, L.; Borgatti, M.; Nicolis, E.; Bianchi, N.; Mancini, I.; Lampronti, I.; Vevaldi, D.; Dall'acqua, F.; Cabrini, G. and Gambari, R. (2010) Virtual screening against nuclear factor kappaB (NF-kappaB) of a focus library: Identification of bioactive furocoumarin derivatives inhibiting NF-kappaB dependent biological functions involved in cystic fibrosis. Bioorg. Med. Chem., 18, 8341-8349.
149. Griesenbach, U. and Alton, E.W.F.W. (2009) Cystic fibrosis gene therapy: successes, failures and hopes for the future. Exp. Rev. Resp. Med., 3, 363-371.
150. Conese, M.; Copreni, E.; Piro, D. and Rejman, J. (2007) Gene and cell therapy for the treatment of cystic fibrosis. Adv. Gene Mol. Cell Ther., 1, 99-119.
151. Legssyer, R.; Huaux, F.; Lebacq, J.; Delos, M.; Marbaix, E.; Lebecque, P.; Lison, D.; Scholte, B.J.; Wallemacq, P. and Leal, T. (2006) Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir. Res., 7, 134.
152. Atkuri, K.R.; Mantovani, J.J.; Herzenberg, L.A. and Herzenberg, L.A. (2007) N-Acetylcysteine--a safe antidote for cysteine/ glutathione deficiency. Curr. Opin. Pharmacol., 7, 355-359.
153. Cantin, A.M.; White, T.B.; Cross, C.E.; Forman, H.J.; Sokol, R.J. and Borowitz, D. (2007) Antioxidants in cystic fibrosis: conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic. Biol. Med., 42, 15-31.
154. Tirouvanziam, R.; Conrad, C.K.; Bottiglieri, T.; Herzenberg, L.A.; Moss, R.B. and Herzenberg, L.A. (2006) High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci. USA, 103, 4628-4633.
155. Suk, J.S.; Lai, S.K.; Wang, Y.Y.; Ensign, L.M.; Zeitlin, P.L.; Boyle, M.P. and Hanes, J. (2009) The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by nonadhesive polymer nanoparticles. Biomaterials, 30, 2591-2597.
156. Riethmuller, J.; Anthonysamy, J.; Serra, E.; Schwab, M.; Doring, G. and Gulbins, E. (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol. Biochem., 24, 65-72.
157. Freedman, S.D.; Blanco, P.G.; Zaman, M.M.; Shea, J.C.; Ollero, M.; Hopper, I.K.; Weed, D.A.; Gelrud, A.; Regan, M.M.; Laposata, M.; Alvarez, J.G. and O'Sullivan, B.P. (2004) Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med., 350, 560-569.
158. Serhan, C.N. (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol., 25, 101-137.
159. Guilbault, C.; Wojewodka, G.; Saeed, Z.; Hajduch, M.; Matouk, E.; De Sanctis, J.B. and Radzioch, D. (2009) Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am. J. Respir. Cell. Mol. Biol., 41, 100-106.
160. Plater-Zyberk, C.; Joosten, L.A.; Helsen, M.M.; Koenders, M.I.; Baeuerle, P.A. and van den Berg, W.B. (2009) Combined blockade of GM-CSF and IL-17 pathways potently suppresses chronic destructive arthritis in a TNF{alpha}independent mouse model. Ann. Rheum. Dis., 68, 721-728.
161. Plater-Zyberk, C.; Joosten, L.A.; Helsen, M.M.; Hepp, J.; Baeuerle, P.A. and van den Berg, W.B. (2007) GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann. Rheum. Dis., 66, 452-457.
162. Panina, P.; Mariani, M.; D'Ambrosio, D. (2006) Chemokine receptors in chronic obstructive pulmonary disease (COPD). Curr. Drug Targets, 7, 669-674.
163. Painter, R.G.; Valentine, V.G.; Lanson, N.A.Jr.; Leidal, K.; Zhang, Q.; Lombard, G.; Thompson, C.; Viswanathan, A.; Nauseef, W.M.; Wang, G. and Wang, G. (2006) CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry, 45, 10260-10269.
164. Verfaillie, C.M. (2002) Hematopoietic stem cells for transplantation. Nat. Immunol., 3, 314-317.
165. Orkin, S.H. and Morrison, S.J. (2002) Stem-cell competition. Nature, 418, 25-27.
166. Prockop, D.J. (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276, 71-74.
167. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S. and Marshak, D.R. (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
168. Loi, R.; Beckett, T.; Goncz, K.K.; Suratt, B.T. and Weiss, D.J. (2006) Limited restoration of cystic fibrosis lung epithelium in vivo with adult marrow derived cells. Am. J. Respir. Crit. Care Med., 173, 171-179.
169. Bruscia, E.M.; Price, J.E.; Cheng, E.-C.; Weiner, S.; Caputo, C.; Ferreira, E.C.; Egan, M.E. and Krause, D.S. (2006) Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantation. Proc. Natl. Acad. Sci. USA, 103, 2965-2970.
170. Bruscia, E.M.; Ziegler, E.C.; Price, J.E.; Weiner, S.; Egan, M.E. and Krause, D.S. (2006) Engraftment of donor-derived epithelial cells in multiple organs following bone marrow transplantation into newborn mice. Stem Cells, 24, 2299-2308.
171. Wang, G.; Bunnell, B.A.; Painter, R.G.; Quiniones, B.C.; Tom, S.; Lanson, N.A.J.; Spees, J.L.; Bertucci, D.; Peister, A.; Weiss, D.J.; Valentine, V.G.; Prockop, D.J. and Kolls, J.K. (2005) Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc. Natl. Acad. Sci. USA, 102, 186-191.
172. Phinney, D.G. (2007) Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle, 6, 2884-2889.
173. Hung, S.C.; Pochampally, R.R.; Chen, S.C.; Hsu, S.C. and Prockop, D.J. (2007) Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells, 25, 2363-2370.
174. Inoue, Y.; Iriyama, A.; Ueno, S.; Takahashi, H.; Kondo, M.; Tamaki, Y.; Araie, M. and Yanagi, Y. (2007) Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Exp. Eye Res., 85, 234-241.
175. Togel, F.; Hu, Z.; Weiss, K.; Isaac, J.; Lange, C. and Westenfelder, C. (2005) Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal. Physiol., 289, F31-F42.
176. Ortiz, L.A.; Gambelli, F.; McBride, C.; Gaupp, D.; Baddoo, M.; Kaminski, N. and Phinney, D.G. (2003) Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl. Acad. Sci. USA, 100, 8407-8411.
177. Mei, S.H.; McCarter, S.D.; Deng, Y.; Parker, C.H.; Liles, W.C. and Stewart, D.J. (2007) Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med., 4, e269.
178. Ortiz, L.A.; Dutreil, M.; Fattman, C.; Pandey, A.C.; Torres, G.; Go, K. and Phinney, D.G. (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. USA, 104, 11002-11007.
179. Gupta, N.; Su, X.; Popov, B.; Lee, J.W.; Serikov, V. and Matthay, M.A. (2007) Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin- induced acute lung injury in mice. J. Immunol., 179, 1855-1863.
180. Uccelli, A.; Pistoia, V. and Moretta, L. (2007) Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol., 28, 219-226.
181. Bruscia, E.M.; Zhang, P.X.; Ferreira, E.; Caputo, C.; Emerson, J.W.; Tuck, D.; Krause, D.S. and Egan, M.E. (2009) Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. Am. J. Respir. Cell Mol. Biol., 40, 295-304.
182. Tabary, O.; Escotte, S.; Couetil, J.P.; Hubert, D.; Dusser, D.; Puchelle, E. and Jacquot, J. (2001) Relationship between Ikappa- Balpha deficiency, NFkappaB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Arch., 443 (Suppl 1), S40-S44.
183. Joseph, T.; Look, D. and Ferkol, T. (2005) NF-κB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell. Mol. Physiol., 288, L471-L479.
184. Venkatakrishnan, A.; Stecenko, A.A.; King, G.; Blackwell, T.R.; Brigham, K.L.; Christman, J.W. and Blackwell, T.S. (2000) Exaggerated activation of nuclear factor-kappaB and altered IkappaBbeta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol., 23, 396-403.